Review





Similar Products

rnasel  (Novus Biologicals)
93
Novus Biologicals rnasel
(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, <t>RNaseL,</t> <t>and</t> <t>PKR</t> KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.
Rnasel, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnasel/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
rnasel - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
mouse monoclonal rnase l antibody 2e9  (Novus Biologicals)
93
Novus Biologicals mouse monoclonal rnase l antibody 2e9
(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, <t>RNaseL,</t> <t>and</t> <t>PKR</t> KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.
Mouse Monoclonal Rnase L Antibody 2e9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal rnase l antibody 2e9/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
mouse monoclonal rnase l antibody 2e9 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
mouse anti rnase l antibody 2e9  (Novus Biologicals)
92
Novus Biologicals mouse anti rnase l antibody 2e9
(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, <t>RNaseL,</t> <t>and</t> <t>PKR</t> KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.
Mouse Anti Rnase L Antibody 2e9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti rnase l antibody 2e9/product/Novus Biologicals
Average 92 stars, based on 1 article reviews
mouse anti rnase l antibody 2e9 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
mouse anti rnase l antibody  (Novus Biologicals)
93
Novus Biologicals mouse anti rnase l antibody
(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, <t>RNaseL,</t> <t>and</t> <t>PKR</t> KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.
Mouse Anti Rnase L Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti rnase l antibody/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
mouse anti rnase l antibody - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
anti rnase l antibody  (Novus Biologicals)
92
Novus Biologicals anti rnase l antibody
(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, <t>RNaseL,</t> <t>and</t> <t>PKR</t> KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.
Anti Rnase L Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti rnase l antibody/product/Novus Biologicals
Average 92 stars, based on 1 article reviews
anti rnase l antibody - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
mouse anti human rnase l specific antibody 2e9  (Novus Biologicals)
92
Novus Biologicals mouse anti human rnase l specific antibody 2e9
(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, <t>RNaseL,</t> <t>and</t> <t>PKR</t> KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.
Mouse Anti Human Rnase L Specific Antibody 2e9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human rnase l specific antibody 2e9/product/Novus Biologicals
Average 92 stars, based on 1 article reviews
mouse anti human rnase l specific antibody 2e9 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

Image Search Results


(A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, RNaseL, and PKR KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.

Journal: bioRxiv

Article Title: Nonsense-mediated decay controls a negative feedback loop in innate immune sensing

doi: 10.1101/2025.05.09.652687

Figure Lengend Snippet: (A) Impact of PIC transfection on 10B inclusion in WT, OAS1, OAS2, OAS3, RNaseL, and PKR KO A549 cells. (B) siRNA-mediated depletion of PKR in OAS3 or RNaseL KO A549 cells. Cells were transfected with siRNA for 72h prior to be transfected with PIC for 6h and RNA harvested for EIF4A2 exon 10B radioactive RT-PCR. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (C) Puromycin-incoroporation assay to measure translation in WT, PKR KO, RNaseL KO, and RNaseL KO + siPKR to monitor the translational output upon stimulation with PIC. (D) Monitoring PKR and RNaseL activation following PAMP transfection in A549. Top, western-blot for pPKR, total PKR, peIF2α, total eIF2α as well as actin (loading control). Bottom, total RNA was run on a Bioanalyzer to monitor RNaseL activation by monitoring rRNA cleavage. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. (E) Monitoring WT vaccinia virus (VACV) or ΔE3L mutant (VACVΔE3L) impact on 10B inclusion. Top, radioactive RT-PCR for EIF4A2 exon 10B; bottom, total RNA on a Bioanalyzer to monitor RNaseL activation. Asterisks denote the cleavage products of ribosomal RNA typical of RNaseL activation. Ordinary one-way ANOVA using Tukey’s multiple comparisons test.

Article Snippet: The commercial primary antibodies used in this study are the following: Actin (Sigma, A5441), eIF2α (Cell Signaling Technology, 9722S), p-eIF2α (Cell Signaling Technology, 9721S), PKR (Cell Signaling Technology, 12297), p-PKR (Abcam, ab32036), puromycin (Millipore Sigma, MABE343), RNaseL (Novus Biologicals, NBP2-80929), UPF1 (Cell Signaling Technology, 9435), p-UPF1 (Millipore Sigma, 07-1016), Vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Transfection, Reverse Transcription Polymerase Chain Reaction, Activation Assay, Western Blot, Control, Virus, Mutagenesis

(A) A549 WT, PKR KO, RNaseL KO as well as RNaseL KO transfected with siRNA against PKR were pre-treated with DMSO or SMG1i (3 μM) for 1h and transfected with 1 μg of PIC and RNA harvested at 6h. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (B) Left, immunofluorescence for IRF3 of DMSO or SMG1i-treated cells transfected with PIC. A549 RNaseL KO were transfected with siPKR for 72h, pre-treated with DMSO or SMG1i (3 μM) for 1h and transfected with 1 μg of PIC prior to IF. Scale bar, 10 μm. Right, quantification of the number of cells with IRF3 nuclear localization. 6 fields were counted for each condition each containing between 14 and 36 cells. Unpaired two-tailed Student’s t-test.

Journal: bioRxiv

Article Title: Nonsense-mediated decay controls a negative feedback loop in innate immune sensing

doi: 10.1101/2025.05.09.652687

Figure Lengend Snippet: (A) A549 WT, PKR KO, RNaseL KO as well as RNaseL KO transfected with siRNA against PKR were pre-treated with DMSO or SMG1i (3 μM) for 1h and transfected with 1 μg of PIC and RNA harvested at 6h. Two-way ANOVA with uncorrected Fisher’s LSD multiple comparisons test. (B) Left, immunofluorescence for IRF3 of DMSO or SMG1i-treated cells transfected with PIC. A549 RNaseL KO were transfected with siPKR for 72h, pre-treated with DMSO or SMG1i (3 μM) for 1h and transfected with 1 μg of PIC prior to IF. Scale bar, 10 μm. Right, quantification of the number of cells with IRF3 nuclear localization. 6 fields were counted for each condition each containing between 14 and 36 cells. Unpaired two-tailed Student’s t-test.

Article Snippet: The commercial primary antibodies used in this study are the following: Actin (Sigma, A5441), eIF2α (Cell Signaling Technology, 9722S), p-eIF2α (Cell Signaling Technology, 9721S), PKR (Cell Signaling Technology, 12297), p-PKR (Abcam, ab32036), puromycin (Millipore Sigma, MABE343), RNaseL (Novus Biologicals, NBP2-80929), UPF1 (Cell Signaling Technology, 9435), p-UPF1 (Millipore Sigma, 07-1016), Vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Transfection, Immunofluorescence, Two Tailed Test

Upon viral infection, dsRNA is produced by most viral infections. This dsRNA, aside from triggering the innate immune sensing pathway and the interferon response, activates RNaseL and PKR, which drastically inhibits translation. In this state of stricking reduction of translation, NMD is also decreased, leading to the accumulation of NMD-decayed isoforms. These isoforms, or the inhibition of NMD itself, feeds back to limit the sensing of dsRNA, in a negative feedback look that will decrease the interferon response as well as RNaseL activation. Created in BioRender. Lynch, K. (2025) https://BioRender.com/3or17n1 .

Journal: bioRxiv

Article Title: Nonsense-mediated decay controls a negative feedback loop in innate immune sensing

doi: 10.1101/2025.05.09.652687

Figure Lengend Snippet: Upon viral infection, dsRNA is produced by most viral infections. This dsRNA, aside from triggering the innate immune sensing pathway and the interferon response, activates RNaseL and PKR, which drastically inhibits translation. In this state of stricking reduction of translation, NMD is also decreased, leading to the accumulation of NMD-decayed isoforms. These isoforms, or the inhibition of NMD itself, feeds back to limit the sensing of dsRNA, in a negative feedback look that will decrease the interferon response as well as RNaseL activation. Created in BioRender. Lynch, K. (2025) https://BioRender.com/3or17n1 .

Article Snippet: The commercial primary antibodies used in this study are the following: Actin (Sigma, A5441), eIF2α (Cell Signaling Technology, 9722S), p-eIF2α (Cell Signaling Technology, 9721S), PKR (Cell Signaling Technology, 12297), p-PKR (Abcam, ab32036), puromycin (Millipore Sigma, MABE343), RNaseL (Novus Biologicals, NBP2-80929), UPF1 (Cell Signaling Technology, 9435), p-UPF1 (Millipore Sigma, 07-1016), Vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Infection, Produced, Inhibition, Activation Assay